Vitalis: Can This Biomaterial Help Tendons Heal Faster?

Tendon injuries are notoriously hard to heal. Even after surgery, recovery can be slow, complications are common, and today’s tools often stop at mechanical repair instead of actively promoting regeneration. But can a biomaterials company built to improve healing in the operating room convince investors it belongs in the future of surgical care? In this episode of Capital Calling, Asser El Ashwah, Founder of Vitalis Regenerative Materials, pitches a company developing regenerative biomaterials designed to improve surgical outcomes. Vitalis’s lead product, BioBlend, is a bio-integrated tool that combines advanced biomaterial formulations with PRP at the point of care, with the goal of enhancing tissue regeneration, reducing complications, and improving recovery in sports medicine procedures and beyond. The company is initially focused on tendon repair, where existing interventions often fail to deliver sustained biological support during healing. (NYU Tandon School of Engineering - https://engineering.nyu.edu/news/asser-el-ashwah-molecular-architect-building-new-biomaterials-new-way-heal-and-new-company) What sets Vitalis apart is its delivery mechanism. Unlike conventional PRP therapies, which can dissipate quickly and lose effectiveness, Vitalis is building a system designed for localized, sustained release of growth factors through a biocompatible polymer formulation. The product is intended to fit directly into existing surgical workflows, turning regenerative medicine from a post-operative add-on into an integrated biosurgical tool. Over time, the company sees broader applications across orthopedic, vascular, reconstructive, and wound healing procedures. (https://nyusternberkleycenter.com/2025/03/revolutionizing-recovery-with-vitalis-regenerative-materials/) Across the table, investors René Bastón of Covenant Venture Capital, Sabriya Stukes, PhD of SOSV, and Doug Hayes of Junto Health & Hubble engage with the pitch as it unfolds. They assess the clinical and commercial need in tendon repair and sports medicine, the defensibility of Vitalis’s biomaterial approach, the practicality of integrating the product into surgeon workflows, and whether a regenerative platform built around sustained growth-factor delivery can scale into a venture-backed medical device company. Capital Calling provides a behind-the-scenes look at a real pitch from both sides of the table. Each episode begins with a live founder pitch and product demo, followed by direct investor questioning. After the pitch, investors enter into a private debrief conversation where they debate the opportunity openly: without the founder present. The founder, on the other hand, enters the On-Call Room to discuss the pitch one-on-one from their perspective. Then, the investors give their verdicts, where feedback is delivered candidly and decisions are made. Produced by Coeus Collective in partnership with the NYU Stern Berkley Center for Entrepreneurship, Capital Calling offers founders, operators, students, and investors an unfiltered look at how early-stage investment decisions actually happen, and what separates compelling ideas from fundable companies. Founders pitch live. Investors decide.